Markets
Photo Illustration of Wegovy semaglutide tablets on a white background
New Wegovy semaglutide tablets (Michael Siluk/Getty Images)

Novo jumps after solid Q1, strong Wegovy pill sales drive improved guidance

The drugmaker reported earnings results on Wednesday.

Novo Nordisk rose in premarket trading after it reported first-quarter earnings results that beat Wall Street expectations and raised its full-year guidance on demand for its new weight-loss pill.

For the first three months of 2026, the drugmaker reported:

  • Sales of 96.8 billion Danish kroner ($15.1 billion). That was significantly ahead of the DKK 70.8 billion ($11.1 billion) analysts polled by FactSet were expecting, though the headline figure was boosted by a ~$4.2 billion one-off from a provision reversal related to the 340B Drug Pricing program.

  • Revenue that included DKK 2.26 billion ($353.6 million) in sales of its new Wegovy pill, more than double the DKK 1.1 billion ($172.5 million) analysts were penciling in.

  • Adjusted operating profit of DKK 32.8 billion ($5.15 billion).

For full-year 2026, the company now expects:

  • Sales and operating profit to fall by between 4% and 12%, having previously forecast a 5% to 13% drop.

Going into the report, investors were eager for signs of how the weight-loss pill, which came to market January 5, is performing. Novo, which was the first to market GLP-1 injections, has lost ground in the past year to Eli Lilly.

Investors will be buoyed by early signs that its Wegovy pill is off to a strong start and not cannibalizing sales of its older treatments.

The pill has been prescribed 2 million times since launch, Novo said, “which marks the strongest-ever GLP-1 volume launch in the US.” About 80% of those patients are taking a GLP-1 for the first time, according to Novo. Eli Lilly gave the same stat for its GLP-1 pill, which came to market in April.

The higher-than-expected sales for the pill were thanks to “pre-launch pipeline fill with wholesalers and telehealth partners,” Novo said. The company said it would launch the pill outside the US in the second half of this year, pending regulatory approval.

Competition has driven down the prices of Novo’s blockbuster GLP-1 shots, Ozempic and Wegovy, resulting in lower sales despite higher volume. The company’s patent on semaglutide, the active ingredient in those shots, has expired this year in key markets like Canada, Brazil, India, and China.

Lilly, the company’s chief rival, reported earnings results last week that showed its GLP-1 shots are still driving sales growth. The company also gave updates for its GLP-1 pill, which came out during the current quarter, and appeared to quell investor fears that the pill had lost too much ground to Novo’s.

More Markets

See all Markets
Dickens, Great Expectations, He said, Aha! would you?

Tech tumbles as momentum stocks run into a blowout jobs report and a wave of profit-taking

The AI trade is under some pressure, taking prices back like... a few days. President Donald Trump is not a fan of the price action.

Trump Administration Considers Reclassifying Marijuana As A Less Dangerous Drug

Trulieve to list on NYSE, a first for US cannabis sector

More may be on the way: several other US cannabis companies have announced reverse stock splits with the intention of listing on a major exchange.

markets

Lululemon’s stretch getting tested: Stock plunges after after outlook is cut

Lululemon shares are down double digits in premarket trading after the company cut its full-year sales and profit outlook, overshadowing a Q1 beat and raising fresh concerns about the brand’s turnaround efforts.

The company now expects fiscal 2026 revenue to be flat to down 1%, compared with its prior forecast for 2% to 4% growth. Guidance for full-year diluted earnings per share was dragged down to a range of $10.95 to $11.15, below the company’s previous guidance of $12.10 to $12.30 and well below Wall Street’s estimate of $13.26.

Key numbers for Q1:

  • EPS of $1.69 vs. the $1.68 expected.

  • Revenue of $2.47 billion vs. the $2.43 billion expected.

The modest top-line beat masked a widening divergence between Lululemons geographic markets. While international revenue rose 22% overall with a 30% increase in Mainland China, the bigger problem remains North America, where revenue fell 5%.

Interim co-CEO and CFO Meghan Frank acknowledged during the earnings call that recent product rollouts underperformed. A highly anticipated yoga campaign failed to generate its expected halo effect across broader product lines.

Profitability metrics took a major hit, with gross margins contracting by 410 basis points to 54.2% due to mounting tariff costs and promotional markdowns. Operating income consequently fell 37% year over year to $276.9 million.

“We experienced spikes of negative commentary in the media and on social channels with regard to our brand, which had an impact on traffic and overall top-line performance,” Frank said during the earnings call. “And second, not all of our product launches have met our expectations. While we have had several successful launches so far this year, we have seen others as we start Q2 not generate the anticipated guest response.”

Lululemons valuation has already been steadily compressing for years. While it was once one of retails richly valued stocks, investors have been questioning whether the company can return to the double-digit growth era.

The results also arrive during a leadership transition. Lululemon announced back in April that former Nike executive Heidi ONeill is set to take over as CEO in September, with investors looking to her to revive growth in North America and restore the brands growth.

As Lululemon faces both macroeconomic pressure and brand-specific challenges, its stock has dropped around 40% year to date.

markets

US job growth skyrocketed in May, blasting past expectations

The US economy added 172,000 jobs in the month of May, the Bureau of Labor Statistics reported Friday, sending 10-year Treasury yields higher.

The strong May job market surprised economists. Experts had predicted only 85,000 new jobs — just half the reported number. The unemployment rate held steady at 4.3%, as expected.

The job growth story is a hopeful spot for the economy as consumers continue to feel inflationary pressure from the Iran war.

Job gains were buoyed by the leisure and hospitality sector, which added 70,000 jobs, as well as local government, healthcare, and education.

Both the March and April jobs reports were revised upward, making them collectively 93,000 higher than previously reported.

Latest Stories

Sherwood Media, LLC and Chartr Limited produce fresh and unique perspectives on topical financial news and are fully owned subsidiaries of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Money, LLC, Robinhood U.K. Ltd, Robinhood Derivatives, LLC, Robinhood Gold, LLC, Robinhood Asset Management, LLC, Robinhood Credit, Inc., Robinhood Ventures DE, LLC and, where applicable, its managed investment vehicles.